Doctronic Secures $40 Million Series B as Autonomous AI Medicine Moves Into Real Clinical Practice
Doctronic, an AI-native healthcare platform legally authorized to practice medicine in the United States, has announced a $40 million Series B funding round co-led by Abstract and Lightspeed Venture Partners, with participation from Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. The new financing brings total funding to more than $65 million, marking the company’s third round in less than 12 months and reinforcing investor confidence in its rapidly scaling model.
The announcement comes alongside a period of accelerated growth. In under six months since its Series A, Doctronic has expanded 15× to reach eight-figure annualized revenue, while nearly tripling repeat patient usage. The platform now serves more than 300,000 unique weekly users, reflecting both rising demand and increasing patient retention across its digital care services.
A central milestone highlighted in the release is Doctronic’s role in Utah’s AI Learning Lab regulatory sandbox. In December 2025, the company became the first AI-native platform authorized to autonomously renew prescriptions, enabling patients to receive medication refills without a direct physician intermediary. The system currently supports approximately 190 medications and operates under strict safety protocols, including continuous monitoring and automatic escalation to licensed physicians for complex or uncertain cases.
Doctronic operates its own clinical practice, licensed across all 50 U.S. states, and maintains full HIPAA compliance. The platform integrates with national healthcare data infrastructure, including QHIN/TEFCA for patient records, Surescripts for medication histories, and First Databank for drug interaction screening. These integrations feed into a multi-agent AI architecture, where specialized models collaborate to perform structured clinical reasoning and generate diagnoses, treatment plans, and documentation.
Unlike traditional AI health assistants that stop at information delivery, Doctronic is designed to take responsibility for clinical outcomes. Its system produces multiple diagnostic pathways, executes treatment recommendations, and in certain cases—such as prescription renewals—acts directly within regulated medical frameworks. The platform also incorporates safeguards such as 24/7 physician oversight escalation and maintains a first-of-its-kind AI medical malpractice insurance structure where applicable.
The company serves both direct-to-consumer users and institutional partners, including health systems, payers, employers, and digital health platforms. AI consultations are offered free of charge and provide patients with several potential diagnoses and treatment options, along with clinically formatted documentation. For cases requiring human intervention, licensed physicians are available via video consultations for standard insurance copays or a fixed fee.
Proceeds from the Series B round will support further expansion into hospital partnerships, academic medical centers, and payer networks, while also funding growth into pediatric care, an area where demand currently exceeds available access. Doctronic is also in active discussions with regulators in additional jurisdictions to extend its AI-powered prescription services beyond Utah.
The funding announcement reflects a broader shift in how AI is being deployed in healthcare—not only as a support tool, but as an operational layer embedded directly into clinical workflows. With increasing scale, regulatory validation, and patient adoption, Doctronic is positioning itself as infrastructure for digital-first care delivery, where AI is not just assisting medical decisions, but actively participating in them.